Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04723394 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 910
- Enrollment target
NCT04723394 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 910 participants.
The verdict
NCT04723394, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 910 participants
- Enrollment target
Study Summary
This Phase III study will assess whether AZD7442 (a combination of 2 mAbs) can safely treat outpatient adults with COVID-19 and prevent either severe COVID-19 or death.
Interventions
- DRUG Placebo
- DRUG AZD7442
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 910 participants |
| Start Date | 2021-01-28 |
| Est. Completion | 2022-10-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04723394
The ClinicalTrials.gov registry entry for NCT04723394 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 910 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04723394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04723394 about?
NCT04723394 is a clinical study titled "Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults". This Phase III study will assess whether AZD7442 (a combination of 2 mAbs) can safely treat outpatient adults with COVID-19 and prevent either severe COVID-19 or death.
What is the current status of trial NCT04723394?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 910 participants. The study started on 2021-01-28. Estimated completion is 2022-10-19.
What interventions are being tested in trial NCT04723394?
The interventions under investigation include: Placebo (DRUG), AZD7442 (DRUG).
Who is sponsoring clinical trial NCT04723394?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.